SuperworthExelixis profit margin EXEL
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 35.3%
- Operating margin, 12 months
- 39.9%
- Net margin on a year earlier
- +8.3 pts
- Peer median
- 22.9%
Over the twelve months to Jul 3, 2026, Exelixis kept 35.3% of its revenue as net profit, with an operating margin of 39.9% and a gross margin of 96.5%.
Five years earlier its net margin was 8.1%.
The median for 10 biotech stocks of a similar size is 22.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 33.7% | 37.6% | 96.4% |
| FY2024 | 24.0% | 27.9% | 96.5% |
| FY2023 | 11.4% | 9.3% | 96.0% |
| FY2022 | 11.3% | 12.5% | 96.4% |
| FY2021 | 16.1% | 20.0% | 96.3% |
| FY2020 | 11.3% | 11.1% | 96.3% |
| FY2019 | 33.2% | 38.2% | 96.6% |
| FY2018 | 80.8% | 51.4% | 96.9% |
| FY2017 | 34.1% | 36.7% | 96.7% |
| FY2016 | −36.7% | −14.7% | n/a |
| FY2015 | n/a | n/a | 89.5% |
| FY2014 | n/a | n/a | 91.9% |
| FY2013 | n/a | n/a | 96.4% |
| FY2012 | n/a | n/a | 100.0% |
| FY2011 | 26.1% | 30.9% | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 35.3% | +8.3 pts | 39.9% | |
| Q1 FY26 | 35.1% | +7.1 pts | 39.4% | |
| Q4 FY25 | 33.7% | +9.7 pts | 37.6% | |
| Q3 FY25 | 29.6% | +7.2 pts | 35.0% | |
| Q2 FY25 | 27.0% | +9.6 pts | 31.4% | |
| Q1 FY25 | 28.0% | +16.9 pts | 33.1% | |
| Q4 FY24 | 24.0% | +12.7 pts | 27.9% | |
| Q3 FY24 | 22.4% | +17.2 pts | 25.1% | |
| Q2 FY24 | 17.4% | +7.8 pts | 18.3% | |
| Q1 FY24 | 11.1% | +1.9 pts | 9.3% | |
| Q4 FY23 | 11.4% | +0.0 pts | 9.3% | |
| Q3 FY23 | 5.2% | −13.6 pts | 2.3% |
Against its peers
Companies in Biotechnology nearest Exelixis' size, closest first, today.
| Company | Profit margin |
|---|---|
| EXELExelixis | 35.3% |
| NBIXNeurocrine Biosciences | 20.9% |
| HALOHalozyme Therapeutics | 24.9% |
| TECHBIO-TECHNE | 15.0% |
| INCYIncyte | 27.7% |
| UTHRUnited Therapeutics | 41.6% |
| RGENRepligen | 5.3% |
| KRYSKrystal Biotech | 54.8% |
| ALNYAlnylam Pharmaceuticals | 16.8% |
| ONCBeOne Medicines | 10.7% |
| REGNRegeneron Pharmaceuticals | 27.9% |
| Peer median | 22.9% |
Where Exelixis ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Exelixis
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.